Company / Shareholders' Equity
Vistagen Therapeutics, Inc. Shareholders' Equity History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$64.7M
FY2023
5-year range
-$5.7M / $92.0M
FY2019-FY2023
Trend
-29.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 8 years, ranging from -$33M in FY2012 to $92M in FY2022.
Based on SEC 10-K filings.
$65M in FY2023 with a 5-year CAGR of +153.7%.
Improved from -$6M to $65M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +153.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +153.7%, indicating consistent growth.
- In FY2023, shareholders' equity decreased 29.6% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $64.7M | -29.6% |
| FY2022 | $92.0M | +1705.4% |
| FY2021 | -$5.7M | -1030.4% |
| FY2018 | $615.8K | +120.7% |
| FY2017 | -$3.0M | +76.3% |
| FY2014 | -$12.6M | +61.8% |
| FY2012 | -$32.9M | -14482.9% |
| FY2011 | -$225.5K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026